Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Strategy Shares Plunge as Bitcoin Premium Evaporates

Felix Baarz by Felix Baarz
November 15, 2025
in Analysis, Bitcoin, Blockchain, Crypto Stocks
0
Strategy Stock
0
SHARES
112
VIEWS
Share on FacebookShare on Twitter

Strategy Inc. is confronting its most severe market downturn in nearly two years. The leading Bitcoin-focused company now sees its stock trading below its net asset value for the first time in 2024, representing a historic breakdown in investor confidence. This development raises fundamental questions about why the firm’s business model—which previously commanded substantial premiums over its underlying Bitcoin holdings—is faltering at this particular moment.

Market Skepticism Reaches Critical Level

The crucial turning point arrived on Friday when Strategy shares collapsed to $201.80, representing a staggering 60% decline from their November 2024 peak of $543. Most significantly, the market value to net asset value (mNAV) ratio dropped to 0.977x. This means investors are now paying less for the company’s equity than the theoretical value of its Bitcoin reserves after accounting for debt and preferred shares.

This threshold was last breached in January 2024, signaling a fundamental shift in market perception. Despite Strategy holding 641,692 Bitcoin valued at $61.9 billion, its market capitalization of approximately $73.8 billion barely exceeds this amount. The longstanding premium that investors willingly paid for exposure through the treasury model has effectively disappeared.

Bitcoin Collapse Triggers Widespread Selling

The panic intensified when Bitcoin prices fell below $95,000 on Friday. This triggered liquidations exceeding $1.3 billion in leveraged cryptocurrency positions, with Strategy absorbing the full impact. The extremely high correlation between MSTR and Bitcoin transformed into a nightmare scenario for shareholders.

Compounding the situation, social media speculation suggested Strategy had liquidated $1 billion worth of Bitcoin, supposedly reducing its holdings from 484,000 to 437,000 BTC. Executive Chairman Michael Saylor immediately refuted these claims, stating “There isn’t a shred of truth to this rumor.” The confusion apparently stemmed from internal wallet transfers that blockchain analysts misinterpreted as sales transactions.

Should investors sell immediately? Or is it worth buying Strategy?

Leadership Responds with Aggressive Buying Plan

Saylor adopted an offensive stance during a CNBC interview, announcing “We’re buying Bitcoin, and we’ll report our next purchases on Monday morning.” He indicated the company is accelerating its acquisition strategy to capitalize on the current market sell-off.

Nevertheless, market participants remained unconvinced. Additional pressure emerged when Vice President and General Counsel Shao Wei-Ming sold 10,668 shares on November 10th and 11th at prices between $234.75 and $249.56, realizing approximately $2.58 million. Although these transactions occurred under a predetermined trading plan connected to Shao’s retirement at year-end, the timing attracted significant scrutiny.

Core Business Model Faces Scrutiny

Bitget CEO Gracy Chen highlighted the central issue: the premium’s collapse undermines the fundamental rationale for Bitcoin treasury companies. If investors no longer pay extra for exposure, what advantage remains over direct Bitcoin ownership?

From a technical perspective, Strategy shares are approaching a critical support level around $138, coinciding with the 200-week moving average. Unless Bitcoin stabilizes soon, further downward pressure appears likely. The coming weeks will determine whether Saylor’s aggressive repurchasing strategy can restore market confidence or whether the era of premium-priced Bitcoin proxy investments has conclusively ended.

Ad

Strategy Stock: Buy or Sell?! New Strategy Analysis from February 7 delivers the answer:

The latest Strategy figures speak for themselves: Urgent action needed for Strategy investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Strategy: Buy or sell? Read more here...

Tags: Strategy
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

February 7, 2026
Repay Holdings Stock
Analysis

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Potbelly Stock
Analysis

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

February 7, 2026
Next Post
Virgin Galactic Stock

Space Stocks Face-Off: High-Risk Tourism Versus Infrastructure Growth

Oxford Lane Capital Stock

Oxford Lane Capital Shares Plunge Following Portfolio Valuation Estimate

QuantumScape Stock

QuantumScape Leadership Exodus Sparks Investor Concerns

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com